Similar results were obtained in CSK-null and PTEN-null N87 cells (Fig. S4A), indicating that loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in HER2-amplified GC cells. This evidence concerns the gene ERBB2 and gastric cancer.